AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?

Novo Nordisk is presented as the more attractive 2026 choice on valuation, trading at 12.1x forward P/E and 3.5x sales versus AbbVie's 16.4x and 7.3x, despite expected FY2026 sales and net-income declines of about 3% and 4%, respectively. Novo generated roughly $47B of FY2025 revenue and a 33% net margin, while AbbVie posted $61.2B of revenue, $4.3B of net income and nearly $17.8B of free cash flow. AbbVie is expected to grow 2026 sales to $67.2B and net income from about $4.2B to $14.6B, supported by Skyrizi, Rinvoq, pipeline prospects and its Apogee Therapeutics acquisition, but it carries patent-cliff, pricing and balance-sheet risks.

Analysis

The relevant dispersion is not “diversified pharma versus GLP-1 growth,” but duration and quality of earnings. ABBV’s expected earnings step-up is likely to invite scrutiny of acquisition accounting, amortization, and whether Skyrizi/Rinvoq can outgrow the combined drag from legacy-product erosion and IRA exposure. Its balance-sheet optics limit flexibility if pipeline assets disappoint, so ABBV should trade more like a high-cash-flow pharmaceutical compounder with event risk than a clean growth multiple re-rating candidate.

NVO’s low multiple embeds a near-term earnings reset, but the stock’s path depends on prescription-share stabilization and realized net pricing—not headline demand. A successful oral obesity launch can expand the treated population by reducing injection aversion and potentially lower distribution friction, yet it may also cannibalize higher-margin injectable demand. LLY remains the cleaner competitive hedge: if the obesity category expands faster than reimbursement pressure, both can work; if efficacy-driven share migration accelerates, LLY captures disproportionate upside while NVO’s valuation floor may prove less durable than consensus assumes.

Over 1-3 months, the key catalysts are quarterly U.S. GLP-1 volume, gross-to-net pricing commentary, formulary placement, and ABBV’s regulatory/pipeline readouts. Over 6-18 months, government pricing implementation and payer prior-authorization behavior matter more than nominal prescription growth. Distributor names MCK, COR, and CAH have limited direct upside from manufacturer price cuts, but sustained specialty-volume growth supports their absolute profit pools; they are lower-beta ways to express continued metabolic-drug penetration.

Contrarian view: NVO’s apparent valuation discount is not automatically cheap because earnings risk is concentrated in one therapeutic franchise and consensus may still underestimate price elasticity under broader coverage. Conversely, ABBV’s near-term earnings acceleration could be more durable than feared if immunology growth offsets legacy erosion, but that requires evidence in organic operating margins rather than adjusted EPS alone.

Key Decisions for Investors

• Initiate a 3-6 month relative-value position: long LLY / short NVO in equal dollar amounts if NVO cannot demonstrate sequential U.S. prescription-share stabilization. Target 10-15% relative return; exit if NVO reports improving share plus stable gross-to-net pricing, which would invalidate the share-loss leg.
• Keep ABBV as a watch-to-buy rather than chase: add only after results confirm immunology growth and operating-margin expansion excluding acquisition-related items. A 12-month upside case requires sustained earnings guidance; reduce or avoid if management cuts guidance or net debt/EBITDA rises following additional M&A.
• For lower-volatility exposure to obesity-treatment utilization, overweight MCK and COR versus broad pharma over 6-12 months. The thesis is incremental specialty-drug volume and services revenue, not a direct pass-through of GLP-1 pricing; reassess if manufacturer volumes decelerate or payer restrictions materially tighten.
• Do not treat NVO’s forward P/E discount as a standalone long signal. Set an alert around its next guidance cycle for realized U.S. net-price trends, oral-product mix, and manufacturing utilization; absent those data, a directional NVO long has unfavorable uncertainty relative to LLY.